Successful management of delirium with dexmedetomidine in a patient with haloperidol-induced neuroleptic malignant syndrome: A case report

Figure 1 Time course of haloperidol administration (Black arrow: 15 mg; white arrow: 10 mg) and dexmedetomidine infusion in relation to changes in BT and serum CK levels. BT: Body temperature; CK: Creatine kinase.

Figure 2 Abdominal computed tomography findings. Digestive tract distension was shown from the esophagus to the small bowel.

Figure 3 Timeline depicting the onset of lorazepam-induced delirium followed by the development of neuroleptic malignant syndrome. CK: Creatine kinase; RASS: Richmond agitation-sedation scale; ICU: Intensive care unit.